Literature DB >> 30731287

Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene.

Ana M Bea1, Itziar Lamiquiz-Moneo2, Victoria Marco-Benedí1, Rocio Mateo-Gallego1, Sofía Pérez-Calahorra1, Estíbaliz Jarauta1, César Martín3, Ana Cenarro1, Fernando Civeira1.   

Abstract

BACKGROUND AND AIMS: The aim of this work was to compared the effect of lipid lowering drugs among familial hypercholesterolemia (FH) subjects with a functional mutation in LDLR (LDLR FH) and FH with the p.(Leu167del) mutation in APOE.
METHODS: We retrospectively selected all adults with the p.(Leu167del) mutation on lipid-lowering treatment (n = 22) attending the Lipid Unit at the Hospital Miguel Servet. Age and sex matched LDLR FH from the same Unit were randomly selected as a control group (n = 44).
RESULTS: The mean percentage reduction in LDLc was significantly higher in the p.(Leu167del) carriers (-52.1%) than in the LDLR FH (-39.7%) (p = 0.040) when on high intensity statins. Similar differences between groups were observed in non-HDLc -49.4% and -36.4%, respectively (p = 0.030).
CONCLUSIONS: Subjects with p.(Leu167del) mutation have a higher lipid-lowering response to statins with or without ezetimibe than LDLR FH. This supports the use of genetics for a more efficient management of FH.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APOE; Familial hypercholesterolemia; Lipid-lowering treatment; p.(Leu167del)

Mesh:

Substances:

Year:  2019        PMID: 30731287     DOI: 10.1016/j.atherosclerosis.2019.01.024

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia.

Authors:  Yara Abou Khalil; Oriane Marmontel; Jean Ferrières; François Paillard; Cécile Yelnik; Valérie Carreau; Sybil Charrière; Eric Bruckert; Antonio Gallo; Philippe Giral; Anne Philippi; Olivier Bluteau; Catherine Boileau; Marianne Abifadel; Mathilde Di-Filippo; Alain Carrié; Jean-Pierre Rabès; Mathilde Varret
Journal:  Int J Mol Sci       Date:  2022-05-21       Impact factor: 6.208

2.  Association of Apolipoprotein E Polymorphisms with White Matter Lesions and Brain Atrophy.

Authors:  ZhiLi Niu; PingAn Zhang; Dong Li; ChengLiang Zhu; LiNa Feng; Ge Xiong; NaNa Song; Pei Tang; Feng Liu
Journal:  Psychiatry Investig       Date:  2020-02-03       Impact factor: 2.505

Review 3.  Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor.

Authors:  Estíbaliz Jarauta; Ana Ma Bea-Sanz; Victoria Marco-Benedi; Itziar Lamiquiz-Moneo
Journal:  Front Genet       Date:  2020-12-03       Impact factor: 4.599

4.  ANGPTL3 gene variants in subjects with familial combined hyperlipidemia.

Authors:  A M Bea; E Franco-Marín; V Marco-Benedí; E Jarauta; I Gracia-Rubio; A Cenarro; F Civeira; I Lamiquiz-Moneo
Journal:  Sci Rep       Date:  2021-03-26       Impact factor: 4.379

5.  The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia.

Authors:  Haochang Hu; Ruoyu Chen; Yingchu Hu; Jian Wang; Shaoyi Lin; Xiaomin Chen
Journal:  Lipids Health Dis       Date:  2021-09-12       Impact factor: 3.876

6.  Evaluation of a novel rapid genomic test including polygenic risk scores for the diagnosis and management of familial hypercholesterolaemia.

Authors:  Emma Neves; Tina Khan; Maggie Williams; Marta Carrera; Winston Banya; Ramon Brugada; Carles Ferrer; Deborah J Morris-Rosendahl; Mahmoud Barbir
Journal:  Glob Cardiol Sci Pract       Date:  2021-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.